Arrakis Therapeutics is a biopharmaceutical company dedicated to pioneering the discovery of small-molecule medicines that directly target RNA. Founded in 2015 and headquartered in Waltham, Massachusetts, the company's mission is to unlock RNA biology to develop new treatments for a wide range of diseases. By focusing on the RNA lifecycle, Arrakis aims to identify novel therapeutic intervention points upstream of traditional protein targets, addressing conditions previously deemed "undruggable."
Key Strategic Focus
Arrakis Therapeutics specializes in developing RNA-targeted small molecules (rSMs) that bind directly to RNA to modulate its function, thereby influencing disease processes. The company's core objectives include:
- Targeting the RNA Lifecycle: By intervening at the RNA level, Arrakis seeks to prevent the expression of disease-causing proteins, offering a novel approach to treatment.
- Addressing Undruggable Targets: Focusing on well-researched protein targets that have been inaccessible with conventional medicines, particularly in oncology, rare genetic diseases, and cardiovascular conditions.
- Expanding Therapeutic Reach: Leveraging their platform to explore a broad spectrum of diseases where RNA plays a critical role.
Financials and Funding
Since its inception, Arrakis has secured significant funding to advance its research and development efforts:
- Series A Financing (February 2017): Raised $38 million led by Canaan Partners, with participation from Advent Life Sciences, Pfizer Inc., Celgene Corporation, Osage University Partners, and biotech industry leader Henri Termeer.
- Series B Financing (April 2019): Secured an additional $75 million to further develop its small-molecule drugs targeting RNA.
- Strategic Partnerships:
- Roche Collaboration (April 2020): Entered into a $190 million licensing agreement granting Roche exclusive rights to develop Arrakis' RNA-targeted therapies for various diseases, including cancer.
- Amgen Partnership (January 2022): Formed a collaboration with Amgen to develop oral drugs targeting and degrading RNA, with an upfront payment of $75 million and potential for additional funding based on research milestones.
Pipeline Development
Arrakis is actively developing a pipeline of rSM medicines targeting various conditions:
- Oncology: Focusing on cancers with high unmet medical needs by targeting RNA associated with tumor growth and survival.
- Rare Genetic Diseases: Developing therapies that modulate RNA to correct or mitigate the effects of genetic mutations.
- Cardiovascular Diseases: Exploring RNA targets involved in cardiovascular pathologies to develop novel treatments.
The company employs a rigorous approach to advance these candidates through preclinical and clinical development stages, with timelines aligned to achieve key milestones efficiently.
Technological Platform and Innovation
Arrakis has developed proprietary platforms to facilitate the discovery and development of rSMs:
- TRYST™ Platform: A high-throughput system integrating bioinformatics tools, assays, and chemical libraries to identify new RNA targets and corresponding small-molecule drugs.
- PEARL-seq™ Platform: Utilizes chemical biology techniques to confirm the binding and functional impact of compounds on RNA within cellular environments.
These platforms enable the systematic identification and optimization of rSMs, setting Arrakis apart in the field of RNA-targeted therapeutics.
Leadership Team
Arrakis is led by a team of experienced professionals with extensive backgrounds in drug discovery and development:
- Michael Gilman, PhD – Chief Executive Officer: Brings a wealth of experience from previous roles, including CEO positions at Obsidian Therapeutics and Padlock Therapeutics, and leadership roles at Biogen Idec and ARIAD Pharmaceuticals.
- Jennifer C. Petter, PhD – Founder & Chief Scientific Officer: An accomplished scientist with a focus on RNA biology, previously serving as Vice President of Chemistry at Celgene and holding positions at Avila Therapeutics, Mersana Therapeutics, and Biogen.
- James Mutamba, PhD – Chief Business Officer: Leads corporate strategy and business development, with prior experience at Pyxis Oncology and Longwood Fund.
- Heather Lounsbury – Senior Vice President, Program & Alliance Management and Operations: Oversees program management and operations, bringing extensive experience in the biotech industry.
- Kathleen McGinness, PhD – Vice President, Platform Biology: Leads platform biology efforts, with a background in developing novel therapeutic platforms and early drug discovery programs.
- Domi Stickens, PhD – Vice President, Discovery and Translational Sciences: Heads discovery and translational sciences, with experience in drug discovery and translational research across multiple therapeutic areas.
Leadership Changes
In October 2016, Michael Gilman, PhD, was appointed as CEO, bringing his extensive experience in biotech leadership to Arrakis.
Competitor Profile
Market Insights and Dynamics
The RNA-targeted therapeutics market is rapidly evolving, driven by advancements in understanding RNA biology and the development of technologies to modulate RNA function. This sector holds significant growth potential, particularly in addressing diseases with limited treatment options.
Competitor Analysis
Key competitors in the RNA-targeted therapeutics space include:
- Alnylam Pharmaceuticals: Specializes in RNA interference (RNAi) therapeutics, with several approved products targeting genetic diseases.
- Ionis Pharmaceuticals: Focuses on antisense oligonucleotide therapies, with a broad pipeline addressing various conditions.
- Moderna Therapeutics: Known for its mRNA-based vaccines and therapies, expanding into treatments for infectious diseases, oncology, and rare diseases.
These companies employ different approaches to RNA-targeted therapies, contributing to a dynamic and competitive landscape.
Strategic Collaborations and Partnerships
Arrakis has established significant collaborations to enhance its research and development capabilities:
- Roche Collaboration (April 2020): A $190 million licensing agreement granting Roche exclusive rights to develop Arrakis' RNA-targeted therapies for various diseases, including cancer.
- Amgen Partnership (January 2022): A collaboration to develop oral drugs targeting and degrading RNA, with an upfront payment of $75 million and potential for additional funding based on research milestones.
These partnerships provide Arrakis with resources and expertise to accelerate the development and commercialization of its therapies.
Operational Insights
Arrakis differentiates itself through its proprietary platforms and focus on small-molecule drugs targeting RNA, offering advantages such as oral bioavailability and broad biodistribution. The company's strategic collaborations further strengthen its position in the competitive landscape.
Strategic Opportunities and Future Directions
Arrakis aims to expand its pipeline into additional therapeutic areas where RNA plays a critical role, leveraging its platforms to address a broader range of diseases. The company is also exploring opportunities to enhance its technological capabilities and establish new partnerships to support its growth objectives.
Contact Information
- Website: arrakistx.com
- LinkedIn: Arrakis Therapeutics
Arrakis Therapeutics continues to advance its mission of developing innovative RNA-targeted small-molecule medicines, aiming to transform the treatment landscape for various diseases.
